Key result
Nicotinic acid (niacin) is evaluated as a potential therapeutic strategy for targeting low HDL-cholesterol in statin-treated patients with hyperlipidaemia and cardiovascular disease.
Key points are not available for this paper at this time.
Niacin evaluation for low HDL in statin-treated patients warrants no practice change; leaves open need for rigorous outcome trials.
Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK Correspondence to Dr Robin P. Choudhury, Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK Tel: +44 1865 234 664; fax: +44 1865 234 667; e-mail: [email protected]
No takes yet. Share an insight, caveat, or question.
Robin P. Choudhury (2010) studied this question. Nicotinic acid (niacin) is evaluated as a potential therapeutic strategy for targeting low HDL-cholesterol in statin-treated patients with hyperlipidaemia and cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: